Physician profile
John Ellis
NPI 1285631242
$848.79
in general payments reported to CMS, 2019-2025
10 companies · $27.61 in 2025
The $27.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $148 · 2022: $40.01 · 2023: $191 · 2024: $258 · 2025: $27.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.16 | 2020-2023 | Breztri |
| Abbott Laboratories | $193.96 | 2021-2025 | Proclaim, Octrode, Eterna |
| Edwards Lifesciences Corporation | $181.84 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $57.32 | 2020-2021 | |
| Boston Scientific Corporation | $55.05 | 2021-2023 | |
| Intuitive Surgical, INC. | $31.55 | 2021 | |
| Ethicon INC. | $22.29 | 2024 | Monarch Platform |
| Biotronik Nro, INC. | $20.32 | 2024 | Prospera |
| Nevro Corp. | $18.35 | 2024 | Senza |
| Hikma Pharmaceuticals USA | $14.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.